Proliferative Diabetic Retinopathy Clinical Trials

1 recruiting

Proliferative Diabetic Retinopathy Trials at a Glance

11 actively recruiting trials for proliferative diabetic retinopathy are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 3 with 4 trials, with the heaviest enrollment activity in Palo Alto, Beijing, and Hagerstown. Lead sponsors running proliferative diabetic retinopathy studies include Beletalent (Zhuhai) Pharmaceutical Co., Ltd, Christian Ophthalmic Surgery Expedition Network, and Annexin Pharmaceuticals AB.

Browse proliferative diabetic retinopathy trials by phase

Treatments under study

About Proliferative Diabetic Retinopathy Clinical Trials

Looking for clinical trials for Proliferative Diabetic Retinopathy? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Proliferative Diabetic Retinopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Proliferative Diabetic Retinopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix, Inc.930 enrolled1 locationNCT07235085
Recruiting
Phase 2

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Normal Tension Glaucoma (NTG)Non-proliferative Diabetic Retinopathy (NPDR)Open-angle Glaucoma (OAG)
Qlaris Bio, Inc.14 enrolled1 locationNCT07354477
Recruiting
Phase 3

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Proliferative Diabetic Retinopathy (PDR)
Jaeb Center for Health Research426 enrolled20 locationsNCT06790784
Recruiting
Phase 2

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

Non-Proliferative Diabetic RetinopathyRetinal Vein Occlusion
Annexin Pharmaceuticals AB12 enrolled1 locationNCT07259928
Recruiting
Not Applicable

Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetic Retinopathy+3 more
Vastra Gotaland Region40 enrolled1 locationNCT06549023
Recruiting
Phase 3

Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

Non-Proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd360 enrolled30 locationsNCT06817265
Recruiting
Not Applicable

Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy

Diabetes Mellitus, Type 2Randomized Controlled TrialDiabetic Retinopathy+2 more
Xuxiang Zhang, MD68 enrolled2 locationsNCT06713720
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

Diabetic RetinopathyNPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd100 enrolled26 locationsNCT06770933
Recruiting
Not Applicable

Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy

Proliferative Diabetic Retinopathy - High Risk
Christian Ophthalmic Surgery Expedition Network150 enrolled1 locationNCT06899529
Recruiting
Early Phase 1

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

PDR - Proliferative Diabetic Retinopathy
Li Xiaorong6 enrolled1 locationNCT06412224
Recruiting
Phase 3

Efficacy of intravitreal triamcinolone acetonide before pan retinal photocoagulation for improvement of visual acuity and macular edema in diabetic retinopathy

Diabetic macular edema in severe non proliferative diabetic retinopathy (NPDR)or proliferative diabetic retinopathy(PDR)
Eye Research Center, Farabi Eye Hospital60 enrolled1 locationACTRN12607000225415